Every Form 4 that VSEE HEALTH INC (VSEE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VSEE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VSEE filings page.
VSee Health, Inc. director and Co-Chief Executive Officer Milton Chen reported an internal restructuring transaction. On May 31, 2026, he transferred 2,870,069 shares of Common Stock to VSee Health, Inc. as consideration under a Stock Purchase Agreement related to his purchase of all equity securities of VSee Lab, Inc. from the company. Following this transaction, his directly held VSee common stock position was reported as 0 shares.
Leonard Jerry reported acquisition or exercise transactions in this Form 4 filing.
VSEE HEALTH, INC. Chief Financial Officer Leonard Jerry received multiple grants of common stock as equity compensation. On March 23, 2026, he was awarded grants including 66,845 shares at $0.37, 40,984 shares at $0.61, 21,552 shares at $1.16, and 20,833 shares at $1.20 per share.
Footnotes explain these shares were issued under the 2024 Incentive Plan as quarterly equity awards owed for the quarters ended March 31, June 30, September 30, and December 31, 2025, with each grant amount based on the common stock closing price on the respective quarter-end date.
Aisiku Imoigele reported acquisition or exercise transactions in this Form 4 filing.
VSee Health, Inc. director and Co-Chief Executive Officer Aisiku Imoigele reported receiving four quarterly equity awards of common stock under the company’s 2024 Incentive Plan, all dated March 23, 2026 and tied to 2025 quarters. The grants cover 128,342 shares at $0.37 per share, 78,689 shares at $0.61, 41,379 shares at $1.16, and 40,000 shares at $1.20, issued as stock compensation pursuant to his executive employment agreement.
O'SULLIVAN COLIN P. reported acquisition or exercise transactions in this Form 4 filing.
VSEE HEALTH, INC. director Colin P. O'Sullivan reported an award of 40,107 shares of common stock, granted under the company’s 2024 Incentive Plan as compensation for his board service for the quarter ended December 31, 2025.
The number of shares was based on the common stock closing price on December 31, 2025, and after this grant he directly owns 108,731 shares of VSEE common stock.
METZGER SCOTT reported acquisition or exercise transactions in this Form 4 filing.
VSEE Health, Inc. director Scott Metzger received a grant of 40,107 shares of common stock at $0.374 per share. This equity award was issued under the company’s 2024 Incentive Plan as compensation for his service as a non-employee director for the quarter ended December 31, 2025.
After this grant, Metzger directly holds a total of 117,356 shares of VSEE Health common stock. The number of shares granted was determined using the common stock’s closing price on December 31, 2025.
VSEE HEALTH, INC. director Kevin Lowdermilk acquired 40,107 shares of common stock at a price of $0.374 per share. These shares were issued under the company’s 2024 Incentive Plan as compensation for his board service for the quarter ended December 31, 2025, based on the stock’s closing price that day. Following this grant, he directly holds 108,731 common shares.
WICKERSHAM DAVID L. reported acquisition or exercise transactions in this Form 4 filing.
VSEE HEALTH, INC. director David L. Wickersham reported an equity award of 40,107 shares of common stock on March 4, 2026. The award was issued under the company’s 2024 Incentive Plan as compensation for his services as a non-employee director for the quarter ended December 31, 2025, with the number of shares based on the closing price of the common stock on December 31, 2025.
After this grant, Wickersham directly holds 1,187,671 shares of VSEE common stock.
VSEE HEALTH, INC. director Fairfax Cydonii V. acquired 40,107 shares of common stock as a stock grant under the company’s 2024 Incentive Plan, issued for services as a non-employee director for the quarter ended December 31, 2025. The grant was based on the common stock’s $0.374 closing price on December 31, 2025 and increased the director’s directly held stake to 108,504 shares of common stock.
VSEE HEALTH, INC. director-related entity FWE Capital LLC converted convertible promissory notes into shares of common stock. On February 23, 2026, the LLC acquired 759,916 shares of common stock at $0.3200 per share and 105,251 shares at $0.6500 per share through derivative conversions.
After these conversions, FWE Capital LLC held 1,147,564 shares and 387,648 shares of VSEE common stock in two separate indirect ownership positions for reporting person David L. Wickersham. The filing notes that the underlying notes included both principal and interest.
VSee Health, Inc. director David L. Wickersham reported an "other" insider transaction involving 100,000 shares of common stock at a stated value of $2.00 per share. According to the filing, he received these shares from Co-Chief Executive Officer Imoigele Aisiku as full repayment of a $200,000 personal loan. Following this transfer, Wickersham directly holds 214,000 shares of VSee Health common stock.
VSee Health, Inc. director and Co-Chief Executive Officer Aisiku Imoigele reported two stock transfers used to repay personal loans. On August 15, he transferred 25,000 common shares at $2.00 per share in full satisfaction of a $50,000 personal loan. On August 14, he transferred 100,000 common shares at $2.00 per share to board member David Wickersham to fully repay a separate $200,000 personal loan made to him by Mr. Wickersham. Following these transactions, his reported direct holdings remained above 3.2 million common shares.
VSee Health, Inc. director David L. Wickersham reported multiple stock awards of common shares on September 19, 2025. Each transaction is coded as an acquisition and represents shares issued under the company's 2024 Incentive Plan in line with its non-employee director compensation policy.
The footnotes explain that these grants compensate his board service for quarters ended September 30, 2025, June 30, 2025, March 31, 2025, December 31, 2024, and September 30, 2024, with the number of shares for each period based on the closing stock price on the relevant date. One award shows 21,870 shares at $0.69 per share, and after that transaction he directly beneficially owned 282,397 common shares.
VSee Health director Scott Metzger reported multiple stock awards granted as director compensation. On September 19, 2025, he acquired several blocks of VSee Health common stock at prices ranging from $0.69 to $2.31 per share, including an award of 21,870 shares at $0.69 per share. After the largest reported award, he directly held 77,249 shares of common stock.
The footnotes state these shares were issued under VSee Health’s 2024 Incentive Plan in line with the company’s non‑employee director compensation policy, covering service as a director for quarters ended between June 30, 2024 and September 30, 2025. Each grant amount was based on the closing market price of the common stock on specified dates, turning Metzger’s quarterly board fees into equity ownership.
VSee Health director Kevin Lowdermilk reported several stock grants of common shares on September 19, 2025. Each transaction is coded as an acquisition and reflects shares issued under the company’s 2024 Incentive Plan in line with the non-employee director compensation policy.
The footnotes state these awards compensate his board service for quarters ended June 30 and September 30, 2024, December 31, 2024, and March 31, June 30, and September 30, 2025. Grant prices range from $0.69 to $2.31 per share, and after the latest award he directly beneficially owns 68,624 shares of VSee Health common stock.
VSee Health, Inc. (VSEE) director Colin P. O’Sullivan reported multiple stock awards of common stock as non-employee director compensation. On September 19, 2025, he acquired several blocks of common stock under the company’s 2024 Incentive Plan, with transaction code "A" indicating grants rather than open-market purchases or sales.
The reported awards include grants such as 21,870 shares at $0.69 per share and smaller blocks including 12,931 shares at $1.16, 12,500 shares at $1.20, 11,029 shares at $1.36, 10,067 shares at $1.49, and 227 shares at $2.31 per share. Footnotes state these shares were issued for O’Sullivan’s service as a director for quarters ended June 30, 2024 through September 30, 2025, based on the respective closing prices on specified dates.
VSee Health, Inc. director Cydonii V. Fairfax reported multiple stock awards of common shares on September 19, 2025. Each award is coded as an acquisition, reflecting stock granted under the company’s 2024 Incentive Plan as part of the non-employee director compensation policy.
The reported grants cover service as a director for quarters ended September 30, 2025, June 30, 2025, March 31, 2025, December 31, 2024, and September 30, 2024, with grant-date prices ranging from $0.69 to $1.49 per share. After the most recent reported award of 21,870 shares at $0.69 per share, Fairfax directly holds 68,397 shares of VSee Health common stock.
VSee Health, Inc. reported that its Chief Financial Officer, Jerry Leonard, acquired several blocks of common stock on September 19, 2025. He received 300,000 shares as a retention bonus under the company’s 2024 Incentive Plan at a stated price of $0 per share. He was also issued 135,724 shares under the same plan in lieu of $295,880 of unpaid cash compensation for services provided during the 2022–2025 fiscal years, based on a per share price of $2.18. In addition, he was granted 125,000 shares for services rendered to VSee Lab, Inc. and iDoc Virtual Telehealth Solutions, Inc. prior to VSee Health’s June 2024 business combination. All positions are reported as directly owned common stock.